Acro Biomedical Co (ROCO:6748) Other Stockholders Equity: NT$-1.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6748 Acro Biomedical Co Ltd ROCO:6748
66 GF Score
Price NT$176.50
GF Value NT$32.15
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Acro Biomedical Co Other Stockholders Equity?

Acro Biomedical Co ROCO:6748 -15.75% 66 Other Stockholders Equity is NT$-1.82 Mil as of Dec. 2025. GuruFocus rates ROCO:6748 with a GF Score™ of 66/100 and a GF Value™ of NT$32.15 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Acro Biomedical Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$-1.82 Mil.

Acro Biomedical Co's quarterly Other Stockholders Equity declined from Dec. 2024 (NT$-0.59 Mil) to Jun. 2025 (NT$-3.14 Mil) but then increased from Jun. 2025 (NT$-3.14 Mil) to Dec. 2025 (NT$-1.82 Mil).

Acro Biomedical Co's annual Other Stockholders Equity increased from Dec. 2023 (NT$-1.48 Mil) to Dec. 2024 (NT$-0.59 Mil) but then declined from Dec. 2024 (NT$-0.59 Mil) to Dec. 2025 (NT$-1.82 Mil).

Acro Biomedical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Acro Biomedical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acro Biomedical Co Other Stockholders Equity Chart

Acro Biomedical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -1.25 -0.37 -1.48 -0.59 -1.82

Acro Biomedical Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 -0.73 -0.59 -3.14 -1.82
ROCO:6748
66GF Score
Acro Biomedical Co Ltd ROCO:6748
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acro Biomedical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-1.82 Mil mean?
Acro Biomedical Co (ROCO:6748) has a Other Stockholders Equity of NT$-1.82 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Acro Biomedical Co and its competitors.
Is Acro Biomedical Co's Other Stockholders Equity too high?
Acro Biomedical Co's current Other Stockholders Equity is NT$-1.82 Mil. Overall, Acro Biomedical Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Other Stockholders Equity compare to VRTX and REGN?
Acro Biomedical Co's Other Stockholders Equity of NT$-1.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Acro Biomedical Co and its competitors. Acro Biomedical Co's current Other Stockholders Equity is NT$-1.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.15, compared to a current price of NT$176.50 — trading 449% above its estimated fair value. The current Other Stockholders Equity is NT$-1.82 Mil. Acro Biomedical Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Other Stockholders Equity is NT$-1.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?

Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued. The current stock price of NT$176.50 is trading 449% above its estimated GF Value™ of NT$32.15. GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.

Key valuation signals for ROCO:6748:

  • Other Stockholders Equity: NT$-1.82 Mil
  • GF Value™: NT$32.15 vs. price of NT$176.50 (449% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acro Biomedical Co Business Description

Address 3rd Floor, No. 57, Luke 2nd Road, Luzhu District, Kaohsiung, TWN
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
66GF Score

Get the complete analysis for ROCO:6748

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$176.50
Price
NT$32.15
GF Value